Comparing two chemotherapy combinations for advanced Ewing's sarcoma
Part of Cancer clinical trials.
This study tests a new way of giving a chemotherapy drug called irinotecan (in a liposome form) along with two other chemotherapy drugs (temozolomide and vincristine) versus the standard form of irinotecan with the same two drugs, for people with advanced Ewing's sarcoma. The goal is to see if the new version is safer and works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 8 and 40 years old.
- You have a confirmed diagnosis of Ewing's sarcoma (a type of cancer often in bones).
- Your first-line chemotherapy (like doxorubicin, cyclophosphamide, or ifosfamide) did not control the cancer, and it either grew during treatment or within 6 months after.
- You have at least one tumor that can be measured on a scan.
- You are generally feeling well enough to do daily activities (ECOG 0-1) and have a life expectancy of at least 3 months.
- Your overall health is good, including blood counts, liver, kidney, and blood clotting function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new schedule of standard chemotherapy drugs to see if it improves outcomes for people with metastatic Ewing sarcoma or CIC-rearranged sarcoma. It is for patients who have not had prior cancer treatment, except possibly one initial cycle of VDC.
This trial tests a weekly dose of a chemotherapy drug wrapped in liposomes (tiny fat bubbles) for people with Ewing sarcoma that has come back or not responded to standard treatments. The goal is to see if this new form of the drug can help when other options have stopped working.
This trial tests a combination of three drugs (dinutuximab beta, irinotecan, and rapamycin) for people with bone cancers like osteosarcoma or Ewing sarcoma that have come back or not responded to treatment. The goal is to see if this combination can shrink or slow the tumors.
This trial tests a combination of three drugs—liposomal irinotecan, temozolomide, and bevacizumab—for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery and has not responded to previous treatments. The goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
Hear when a new Ewing's Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.